📊 APVO Key Takeaways
Is Aptevo Therapeutics Inc. (APVO) a Good Investment?
Aptevo Therapeutics is in severe financial distress with collapsing revenue (-74.7% YoY), massive operating losses (-$20.3M on only $3.1M revenue), and negative free cash flow of -$20.4M. Despite adequate liquidity, the company is burning cash at an unsustainable rate with no clear path to profitability, characteristic of a pre-revenue or failed-asset biotech with fundamental business viability concerns.
Aptevo Therapeutics shows very weak fundamentals, with revenue down 74.7% year over year and extremely negative operating and net margins, indicating the business is not currently converting its pipeline or collaborations into sustainable income. While the balance sheet has low leverage and meaningful cash relative to liabilities, the company is burning over $20M in annual operating cash flow against only $21.06M of cash, creating significant funding and dilution risk unless operating performance improves materially.
Why Buy Aptevo Therapeutics Inc. Stock? APVO Key Strengths
- Strong current ratio of 4.03x provides near-term liquidity runway
- Zero long-term debt eliminates bankruptcy risk from leverage
- Maintains $21.1M cash balance for operational continuity in short-term
- Strong liquidity profile with a 4.03x current ratio and no long-term debt
- Cash balance of $21.06M exceeds total liabilities of $9.60M, providing short-term financial flexibility
- Positive equity base of $17.39M supports balance sheet stability relative to many distressed biotech peers
APVO Stock Risks: Aptevo Therapeutics Inc. Investment Risks
- Revenue collapse of 74.7% YoY indicates loss of commercial traction or product failure
- Operating burn rate of $20.3M annually with only $3.1M revenue is unsustainable
- Negative free cash flow of -$20.4M will deplete $21.1M cash within ~12 months at current burn rate
- Severely negative margins (operating -652%, net -647%) indicate no viable business model
- Pharmaceutical sector with failed commercial execution faces high risk of total equity loss
- Revenue collapsed 74.7% year over year, signaling poor growth quality and unstable commercialization or collaboration income
- Operating loss of $20.32M and free cash flow of -$20.39M indicate an unsustainable cash burn rate
- Severely negative profitability metrics, including -652.4% operating margin and -115.9% ROE, reflect weak business economics
Key Metrics to Watch
- Quarterly revenue trend - any stabilization or further deterioration
- Cash burn rate and runway months - critical given current trajectory
- Operating expense reduction initiatives - cost control measures
- Quarterly operating cash flow - whether negative trends persist
- Any new partnership, licensing, or asset sale announcements
- Quarterly cash burn versus cash and equivalents
- Revenue trajectory and any improvement in operating loss
Aptevo Therapeutics Inc. (APVO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.03x current ratio provides a solid financial cushion.
APVO Profit Margin, ROE & Profitability Analysis
APVO vs Healthcare Sector: How Aptevo Therapeutics Inc. Compares
How Aptevo Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aptevo Therapeutics Inc. Stock Overvalued? APVO Valuation Analysis 2026
Based on fundamental analysis, Aptevo Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aptevo Therapeutics Inc. Balance Sheet: APVO Debt, Cash & Liquidity
APVO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aptevo Therapeutics Inc.'s revenue has declined by 90% over the 5-year period, indicating business contraction. The most recent EPS of $-31,460.23 indicates the company is currently unprofitable.
APVO Revenue Growth, EPS Growth & YoY Performance
APVO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $3.1M | $2.8M | $-0.50 |
| Q2 2023 | $3.1M | $2.8M | $-0.72 |
| Q1 2023 | $3.1M | $2.8M | $0.26 |
| Q3 2022 | $3.1M | -$7.0M | $-1.43 |
| Q2 2022 | $3.1M | -$7.3M | $-1.75 |
| Q1 2022 | $2.4M | -$7.3M | N/A |
| Q3 2021 | $1.5M | $2.9M | N/A |
| Q2 2021 | $473.0K | $2.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aptevo Therapeutics Inc. Dividends, Buybacks & Capital Allocation
APVO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aptevo Therapeutics Inc. (CIK: 0001671584)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APVO
What is the AI rating for APVO?
Aptevo Therapeutics Inc. (APVO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APVO's key strengths?
Claude: Strong current ratio of 4.03x provides near-term liquidity runway. Zero long-term debt eliminates bankruptcy risk from leverage. ChatGPT: Strong liquidity profile with a 4.03x current ratio and no long-term debt. Cash balance of $21.06M exceeds total liabilities of $9.60M, providing short-term financial flexibility.
What are the risks of investing in APVO?
Claude: Revenue collapse of 74.7% YoY indicates loss of commercial traction or product failure. Operating burn rate of $20.3M annually with only $3.1M revenue is unsustainable. ChatGPT: Revenue collapsed 74.7% year over year, signaling poor growth quality and unstable commercialization or collaboration income. Operating loss of $20.32M and free cash flow of -$20.39M indicate an unsustainable cash burn rate.
What is APVO's revenue and growth?
Aptevo Therapeutics Inc. reported revenue of $3.1M.
Does APVO pay dividends?
Aptevo Therapeutics Inc. does not currently pay dividends.
Where can I find APVO SEC filings?
Official SEC filings for Aptevo Therapeutics Inc. (CIK: 0001671584) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APVO's EPS?
Aptevo Therapeutics Inc. has a diluted EPS of $-11.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APVO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aptevo Therapeutics Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APVO stock overvalued or undervalued?
Valuation metrics for APVO: ROE of -115.9% (sector avg: 15%), net margin of -647.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APVO stock in 2026?
Our dual AI analysis gives Aptevo Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APVO's free cash flow?
Aptevo Therapeutics Inc.'s operating cash flow is $-20.4M, with capital expenditures of $29.0K. FCF margin is -654.6%.
How does APVO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -647.4% (avg: 12%), ROE -115.9% (avg: 15%), current ratio 4.03 (avg: 2).